Opdivo trial stopped early as BMS med tops Afinitor in kidney cancer

Bristol-Myers Squibb ($BMY) hit a big milestone in its quest to expand use of the immunotherapy Opdivo in a slate of cancer types. In a late-stage kidney cancer study, Opdivo showed a survival advantage over Novartis' ($NVS) Afinitor, prompting a monitoring committee to stop the trial early. Release

Suggested Articles

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.

Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.